Tag:

AstraZeneca

Latest Headlines

Latest Headlines

AstraZeneca grabs a surprise early approval for its $2B cancer contender

Despite loud objections from its advisers, the FDA granted an accelerated approval to AstraZeneca's ovarian cancer treatment, clearing an oral therapy the U.K. drugmaker believes will bring in blockbuster sales.

AstraZeneca snags EU approval for first-in-class cancer fighter Lynparza

AstraZeneca scored European approval for its ovarian cancer-treating drug Lynparza (olaparib), expanding its cancer portfolio at a time when the company is trying to show investors that it's better off independent.

UPDATED: AstraZeneca targets U.K. plant for closure

Just a week after saying it would close a plant in the U.S. and whack 180 jobs, AstraZeneca said that a facility in the U.K. will also close and 250 more jobs will be cut there.

AstraZeneca closing U.S. plant, costing 180 jobs

AstraZeneca has been fighting a losing legal battle to protect the patent on its asthma drug Pulmicort Respules, and a plant in Massachusetts will pay part of the price. The U.K. drugmaker says it will close the plant next year, putting 180 workers out of jobs.

AstraZeneca scores a victory in pay-for-delay Nexium case

Last year, the U.S. Supreme Court slapped the industry with an unfavorable pay-for-delay verdict, ruling that consumers have the right to challenge brand-name drugmakers' patent settlements with generics companies. Now, in what could become a bellwether case for the industry, AstraZeneca scored a victory federal court as a jury found that the company's deal with Ranbaxy Laboratories to delay a generic launch of its heartburn med Nexium was not anticompetitive.   

AstraZeneca pay-to-delay could cost it and the industry billions of dollars

The U.S. Supreme Court last year refused to side with the industry in so-called pay-to-delay deals. Instead it pulled back the insulating legal blanket the industry had been wrapped in, ruling the deals must be fought on a case-by-case basis. Now AstraZeneca is first up to see how juries will respond, facing potentially billions of dollars in damages if it loses.

Odds for a Pfizer-AZ matchup? All over the map, if you listen to analysts

Forget the odds on Thanksgiving Day football games. What's your bet on Pfizer lodging another bid for AstraZeneca?

Amgen, AstraZeneca's brodalumab beats J&J's Stelara in 2nd PhIII psoriasis showdown

Amgen and AstraZeneca have racked up their third straight Phase III win for brodalumab in plaque psoriasis, beating J&J's Stelara in a head-to-head study. The news comes just two weeks after the pharma partners posted their latest positive results, positioning them for a run at regulators on both sides of the Atlantic.

With Duaklir nod in EU, AstraZeneca scores first new drug from Almirall buyout

With the EU approval of COPD med Duaklir, AstraZeneca is getting exactly what it wanted when it sealed a deal for Almirall's respiratory portfolio earlier this month. The only problem? Calling the market crowded is an understatement.

AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it

With the EU approval of COPD med Duaklir, AstraZeneca is getting exactly what it wanted when it sealed a deal for Almirall's respiratory portfolio earlier this month. The only problem? Calling the market crowded is an understatement.